TradeFlare's AI research teams analysed PCRX on 7 market nights between May 7, 2026 and October 13, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 13, 2026 | HOLD | $36.35 | — / — | not yet | not yet | The stock is currently in a holding pattern due to the pending acquisition and lack of clear directional conviction. |
| August 11, 2026 | HOLD | $25.02 | — / — | -1.6% | +6.2% | Continued positive developments in gene therapy pipeline. |
| August 10, 2026 | HOLD | $25.02 | — / — | -4.9% | +5.9% | Continued positive developments in gene therapy pipeline. |
| August 6, 2026 | HOLD | $24.87 | — / — | -9.4% | +4.0% | Continued positive momentum from Q2 earnings and revenue beat. |
| August 5, 2026 | HOLD | $27.62 | — / — | -4.7% | +6.9% | Potential for a breakout above the 52-week high if momentum continues. |
| May 8, 2026 | HOLD | $23.64 | $25.90 / $21.28 | -2.2% | -1.2% | The current market and stock conditions do not present a clear, high-conviction trading opportunity. |
| May 7, 2026 | BUY | $23.69 | — / — | -0.5% | -3.8% | The current market regime is bullish, but the stock's internal metrics do not support a buy decision. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.